Category Archives: Policy

#AI – Diagnosis on demand – and disappointment

Thursday evening’s Horizon, subtitled ‘The Computer will see you now’ is the latest in a lengthening line of programmes and books that purport to critique today’s medical zeitgeist: Artificial Intelligence in healthcare. It was entertaining. I understand. Who would have … Continue reading

Posted in Information, Policy, Technology | Tagged , , , , , , | Leave a comment

Are pharmaceutical mega-mergers in the public interest?

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development –  R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading

Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Medical advisory body “NICE” should not spend too much time valuing drugs.

The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading

Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Prevention is better than cure.

The economic consequences of preventing illness are highly complex. Just comparing the costs of prevention with the direct treatment costs that should be avoided is far too simplistic. The true economic impact of preventative measures can often only be assessed … Continue reading

Posted in Alcohol, Business, Children, Elderly, Health Bill, Healthcare, Information, Jeremy Hunt, NHS, Obesity, Patient choice, Patients, Policy, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: The NHS Constitution- the turning point?

The Health and Social Care Act 2012 has always had my support. All my concerns were addressed in the final Act. The thrust of the Bill remained intact.  However, like many other people I was dismayed by the strength of … Continue reading

Posted in Andrew Lansley, Department of Health, Health Bill, Health Team, Healthcare, Hospitals, Innovation, Jeremy Hunt, NHS, Patients, Policy | Tagged , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.

David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading

Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Do private patients in the UK help or harm the NHS?

Private medicine like private education and first-class travel can stir up feelings of resentment between the “haves” and “have-nots”. A short blog like this one has no possibility of uniting stereotypical politicians from the left and right wings of politics. … Continue reading

Posted in Business, Department of Health, Drugs, Elderly, GPs, Health Bill, Health Team, Healthcare, Hospitals, Inequality, mental health, NHS, Nursing, Patient choice, Patients, Pharma, Policy, Private, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment